Preparation, optimization, and characterization of chitosan-coated solid lipid nanoparticles for ocular drug delivery

Abstract

The present study aimed to develop and optimize chitosan coated solid lipid nanoparticles (chitosan-SLNs) encapsulated with methazolamide. Chitosan-SLNs were successfully prepared by a modified oil-in-water emulsification-solvent evaporation method with glyceryl monostearate as the solid lipid and phospholipid as the surfactant. Systematic screening of formulation factors was carried out. The optimized formula for preparation was screened by orthogonal design as well as Box-Behnken design with entrapment efficiency, particle size and zeta potential as the indexes. The entrapment efficiency of the optimized formulation (methazolamide-chitosan-SLNs) prepared was (58.5±4.5)%, particle size (247.7±17.3) nm and zeta potential (33.5±3.9) mV. Transmission electron microscopy showed homogeneous spherical particles in the nanometer range. A prolonged methazolamide in vitro release profile was obtained in the optimized chitosan-SLNs suspension compared with methazolamide solution. No ocular damages were observed in the susceptibility test on albino rabbits. The results suggest that the combination of orthogonal design and Box-Behnken design is efficient and reliable in the optimization of nanocarriers, and chitosan-SLNs is a potential carrier for ophthalmic administration.

Keywords

solid lipid nanoparticle / orthogonal design / Box-Behnken design / ophthalmic administration / chitosan

References

[1] Almeida AJ, Souto E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins[J]. Adv Drug Deliv Rev, 2007, 59(6): 478–490

[2] Souto EB, Müller RH. Lipid nanoparticles: effect on bioavailability and pharmacokinetic changes[J]. Handb Exp Pharmacol, 2010, 197(197): 115–141

[3] Wong HL, Bendayan R, Rauth AM, Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles[J]. Adv Drug Deliv Rev, 2007, 59(6): 491–504

[4] Li R, Jiang S, Liu D, A potential new therapeutic system for glaucoma: solid lipid nanoparticles containing methazolamide[J]. J Microencapsul, 2011, 28(2): 134–141

[5] Attama AA, Reichl S, Müller-Goymann CC. Diclofenac sodium delivery to the eye: in vitro evaluation of novel solid lipid nanoparticle formulation using human cornea construct[J]. Int J Pharm, 2008, 355(1-2): 307–313

[6] de la Fuente M, Raviña M, Paolicelli P, Chitosan-based nanostructures: a delivery platform for ocular therapeutichitosan[J]. Adv Drug Deliv Rev, 2010, 62(1): 100–117

[7] Fujitani K, Gadaria N, Lee K I, Corneal permeability changes in dry eye disease: an observational study[J]. Bmc Ophthalmology, 2016, 16(1): 1–6

[8] Paolicelli P, de la Fuente M, Sánchez A, Chitosan nanoparticles for drug delivery to the eye[J]. Expert Opin Drug Deliv, 2009, 6(3): 239–253

[9] Gratieri T, Gelfuso GM, Rocha EM, A poloxamer/chitosan in situ forming gel with prolonged retention time for ocular delivery[J]. Eur J Pharm Biopharm, 2010, 75(2): 186–193

[10] Elmizadeh H, Khanmohammadi M, Ghasemi K, Preparation and optimization of chitosan nanoparticles and magnetic chitosan nanoparticles as delivery systems using Box-Behnken statistical design[J]. J Pharm Biomed Anal, 2013, 80: 141–146

[11] Amoozgar Z, Park J, Lin Q, Low molecular-weight chitosan as a pH-sensitive stealth coating for tumor-specific drug delivery[J]. Mol Pharm, 2012, 9(5): 1262–1270

[12] Mun EA, Morrison PWJ, Williams AC, On the barrier properties of the cornea: a microscopy study of the penetration of fluorescently labeled nanoparticles, polymers, and sodium fluorescein[J]. Mol Pharm, 2014, 11(10): 3556–3564

[13] Sandri G, Bonferoni MC, Gökçe EH, Chitosan-associated SLN: in vitro and ex vivo characterization of cyclosporine A loaded ophthalmic systems[J]. J Microencapsul, 2010, 27(8): 735–746

[14] Garcia-Fuentes M, Prego C, Torres D, A comparative study of the potential of solid triglyceride nanostructures coated with chitosan or poly (ethylene glycol) as carriers for oral calcitonin delivery[J]. Eur J Pharm Sci, 2005, 25(1): 133–143

[15] Hermans K, Van den Plas D, Everaert A, Full factorial design, physicochemical characterisation and biological assessment of cyclosporine A loaded cationic nanoparticles[J]. Eur J Pharm Biopharm, 2012, 82(1): 27–35

[16] Ridolfi DM, Marcato PD, Justo GZ, Chitosan-solid lipid nanoparticles as carriers for topical delivery of tretinoin[J]. Colloids Surf B Biointerfaces, 2012, 93(1): 36–40

[17] Nagarwal RC, Kumar R, Pandit JK. Chitosan coated sodium alginate-chitosan nanoparticles loaded with 5-FU for ocular delivery: in vitro characterization and in vivo study in rabbit eye[J]. Eur J Pharm Sci, 2012, 47(4): 678–685

[18] Hao J, Fang X, Zhou Y, Development and optimization of solid lipid nanoparticle formulation for ophthalmic delivery of chloramphenicol using a Box-Behnken design[J]. Int J Nanomedicine, 2011, 6: 683–692

[19] Motwani SK, Chopra S, Talegaonkar S, Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: formulation, optimisation and in vitro characterisation[J]. Eur J Pharm Biopharm, 2008, 68(3): 513–525

[20] Kaur IP, Singh M, Kanwar M. Formulation and evaluation of ophthalmic preparations of acetazolamide[J]. Int J Pharm, 2000, 199(2): 119–127

[21] Wang F, Chen L, Zhang D, Methazolamide-loaded solid lipid nanoparticles modified with low-molecular weight chitosan for the treatment of glaucoma: vitro and vivo study[J]. J Drug Target, 2014, 22(9): 849–858

[22] Pepić I, Hafner A, Lovrić J, A nonionic surfactant/chitosan micelle system in an innovative eye drop formulation[J]. J Pharm Sci, 2010, 99(10): 4317–4325

[23] Diebold Y, Jarrín M, Sáez V, Ocular drug delivery by liposome-chitosan nanoparticle complexes (LCHITOSAN-NP)[J]. Biomaterials, 2007, 28(8): 1553–1564

[24] Wang XQ, Fan JM, Liu YO, Bioavailability and pharmacokinetichitosan of sorafenib suspension, nanoparticles and nanomatrix for oral administration to rat[J]. Int J Pharm, 2011, 419(1-2): 339–346

[25] Yang X, Yang M, Hou B, Optimization of dispersive liquid-liquid microextraction based on the solidification of floating organic droplets using an orthogonal array design and its application for the determination of fungicide concentrations in environmental water samples[J]. J Sep Sci, 2014, 37(15): 1996–2001

[26] Hao J, Wang F, Wang X, Development and optimization of baicalin-loaded solid lipid nanoparticles prepared by coacervation method using central composite design[J]. Eur J Pharm Sci, 2012, 47(2): 497–505

[27] Sanad RA, Abdel Malak NS, El-Bayoomy TS, Preparation and characterization of oxybenzone-loaded solid lipid nanoparticles (SLNs) with enhanced safety and sunscreening efficacy: SPF and UVA-PF[J]. Drug Discov Ther, 2010, 4(6): 472–483

[28] Mahmoud AA, El-Feky GS, Kamel R, Chitosan/sulfobutylether-β-cyclodextrin nanoparticles as a potential approach for ocular drug delivery[J]. Int J Pharm, 2011, 413(1–2): 229–236

[29] Gökçe EH, Sandri G, Eğrilmez S, Cyclosporine a-loaded solid lipid nanoparticles: ocular tolerance and in vivo drug release in rabbit eyes[J]. Curr Eye Res, 2009, 34(11): 996–1003

[30] Zhang J, Zhu X, Jin Y, Mechanism study of cellular uptake and tight junction opening mediated by goblet cell-specific trimethyl chitosan nanoparticles[J]. Mol Pharm, 2014, 11(5): 1520–1532

[31] Maren TH, Haywood JR, Chapman SK, The pharmacology of methazolamide in relation to the treatment of glaucoma[J]. Invest Ophthalmol Vis Sci, 1977, 16(8): 730–742

[32] Müller-Goymann CC. Physicochemical characterization of colloidal drug delivery systems such as reverse micelles, vesicles, liquid crystals and nanoparticles for topical administration[J]. Eur J Pharm Biopharm, 2004, 58(2): 343–356

[33] Luo Q, Zhao J, Zhang X, Nanostructured lipid carrier (NLC) coated with Chitosan Oligosaccharides and its potential use in ocular drug delivery system[J]. Int J Pharm, 2011, 403(1–2): 185–191

[34] Kean T, Thanou M. Biodegradation, biodistribution and toxicity of chitosan[J]. Adv Drug Deliv Rev, 2010, 62(1): 3–11

Acknowledgments

This work was supported by grants from the National Natural Science Foundation of China (81100977).

RIGHTS & PERMISSIONS

2018 2018 by the Journal of Biomedical Research.